LXRX Stock Price Chart More Charts

LXRX Price/Volume Stats

Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.

LXRX Price Forecast Based on DCF Valuation

We started the process of determining a valid price forecast for Lexicon Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lexicon Pharmaceuticals Inc ranked in the 65st percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Lexicon Pharmaceuticals Inc ended up being:

• The company's compound free cash flow growth rate over the past 3.66 years comes in at -0.13%; that's greater than only 14.41% of US stocks we're applying DCF forecasting to.
• Lexicon Pharmaceuticals Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 5.81% of tickers in our DCF set.
• As a business, Lexicon Pharmaceuticals Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.

RSCF, AMN, FONR, AMED, and CPHI can be thought of as valuation peers to LXRX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.